IS1940B - Lyfjasamsetningar sem innihalda HMG afoxunarensímlata - Google Patents

Lyfjasamsetningar sem innihalda HMG afoxunarensímlata

Info

Publication number
IS1940B
IS1940B IS6254A IS6254A IS1940B IS 1940 B IS1940 B IS 1940B IS 6254 A IS6254 A IS 6254A IS 6254 A IS6254 A IS 6254A IS 1940 B IS1940 B IS 1940B
Authority
IS
Iceland
Prior art keywords
pharmaceutical formulations
formulations containing
enzyme inhibitors
reducing enzyme
containing hmg
Prior art date
Application number
IS6254A
Other languages
English (en)
Other versions
IS6254A (is
Inventor
Richard Creekmore Joseph
Alfred Wiggins Norman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS1940(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6254A publication Critical patent/IS6254A/is
Publication of IS1940B publication Critical patent/IS1940B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6254A 2000-01-26 2002-01-29 Lyfjasamsetningar sem innihalda HMG afoxunarensímlata IS1940B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
PCT/GB2000/003014 WO2001054668A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor

Publications (2)

Publication Number Publication Date
IS6254A IS6254A (is) 2002-01-29
IS1940B true IS1940B (is) 2004-07-16

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
IS6254A IS1940B (is) 2000-01-26 2002-01-29 Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
IS6480A IS6480A (is) 2000-01-26 2002-07-23 Lyfjasamsetningar sem samanstanda af HMG COA redúktasa lata
IS8620A IS2805B (is) 2000-01-26 2007-03-07 Lyfjaefnablanda sem inniheldur (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl]-(3R,5S)-3,5-díhýdroxýhept-6-ensýru eða lyfjafræðilega hæft salt þar af

Family Applications After (2)

Application Number Title Priority Date Filing Date
IS6480A IS6480A (is) 2000-01-26 2002-07-23 Lyfjasamsetningar sem samanstanda af HMG COA redúktasa lata
IS8620A IS2805B (is) 2000-01-26 2007-03-07 Lyfjaefnablanda sem inniheldur (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl]-(3R,5S)-3,5-díhýdroxýhept-6-ensýru eða lyfjafræðilega hæft salt þar af

Country Status (48)

Country Link
US (2) US6548513B1 (is)
EP (6) EP2266540A1 (is)
JP (3) JP3267960B2 (is)
KR (3) KR100698333B1 (is)
CN (3) CN101028268A (is)
AP (2) AP1879A (is)
AR (3) AR025055A1 (is)
AT (3) ATE232088T1 (is)
AU (5) AU2000264559A1 (is)
BE (2) BE1013414A5 (is)
BG (4) BG65234B1 (is)
BR (2) BR0003365A (is)
CA (3) CA2315141C (is)
CH (2) CH691347A5 (is)
CL (1) CL2007001807A1 (is)
CR (3) CR6568A (is)
CZ (3) CZ299105B6 (is)
DE (3) DE10038110B4 (is)
DK (3) DK1223918T3 (is)
EE (3) EE05586B1 (is)
ES (2) ES2171123B1 (is)
FI (3) FI121365B (is)
FR (2) FR2795324B1 (is)
GB (3) GB0001621D0 (is)
HK (4) HK1048950A1 (is)
HR (3) HRP20020097B1 (is)
HU (2) HUP0003111A3 (is)
IL (4) IL147870A (is)
IS (3) IS1940B (is)
IT (2) ITTO20000780A1 (is)
ME (4) MEP33808A (is)
MY (2) MY123650A (is)
NL (2) NL1015859C2 (is)
NO (4) NO327675B1 (is)
NZ (2) NZ531474A (is)
PL (2) PL341855A1 (is)
PT (3) PT102504A (is)
RS (1) RS50201B (is)
RU (2) RU2206324C1 (is)
SE (2) SE523471C2 (is)
SI (1) SI1223918T1 (is)
SK (2) SK283872B6 (is)
TR (3) TR200701171T2 (is)
TW (2) TWI228050B (is)
UA (2) UA51853C2 (is)
WO (2) WO2001054668A1 (is)
YU (1) YU52902A (is)
ZA (2) ZA200003997B (is)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
IL152179A (en) † 2000-04-10 2009-06-15 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
JPWO2004016262A1 (ja) * 2002-08-12 2005-12-02 協和醗酵工業株式会社 アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
EP1562912A2 (en) * 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
TWI344363B (en) * 2003-09-12 2011-07-01 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) * 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
HUE033015T2 (en) * 2004-05-04 2017-11-28 Innophos Inc Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
PL1851206T3 (pl) * 2005-02-22 2013-01-31 Teva Pharma Rozuwastatyna i jej wolne od alkilenowych eterów sole oraz sposób ich wytwarzania
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
RU2303980C2 (ru) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Лекарственная форма с антиагрегационным действием и способ ее изготовления
JP2009515816A (ja) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
MX2007004427A (es) * 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
HRP20120957T1 (hr) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid
EA016713B1 (ru) * 2005-10-31 2012-07-30 Кова Ко., Лтд. Таблетка с насечкой, обладающая превосходной фотостабильностью
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en) * 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
SI2086945T1 (sl) * 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
WO2009095934A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
CA2727630A1 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
US20110098315A1 (en) * 2008-06-27 2011-04-28 Farhad Sayyad Farshi Pharmaceutical compositions of rosuvastatin calcium
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (en) 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
SG194586A1 (en) 2011-05-20 2013-12-30 Astrazeneca Uk Ltd Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
ES2903149T3 (es) * 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
KR20140111982A (ko) 2013-03-12 2014-09-22 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20170083071A (ko) 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
WO2017205844A2 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP7274428B2 (ja) 2017-06-09 2023-05-16 リンドラ セラピューティクス， インコーポレイティド 放出速度調節フィルムを有する胃内滞留システム
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
ZA891696B (en) * 1988-10-06 1990-11-28 Sandoz Ltd Pyrimidinyl-substituted hydroxyacids,lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ATE112491T1 (de) 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
DK0680320T3 (da) 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
WO1997023200A1 (en) * 1995-12-22 1997-07-03 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
AU755616B2 (en) 1998-06-05 2002-12-19 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1253921A4 (en) 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

Also Published As

Publication number Publication date
MEP33708A (hr) 2010-10-10
ME00202B (me) 2010-10-10
RU2002122752A (ru) 2004-03-10
FI20001749L (fi) 2001-07-27
CN101028268A (zh) 2007-09-05
HK1036934A1 (en) 2002-01-25
CZ298411B6 (cs) 2007-09-26
RU2264210C2 (ru) 2005-11-20
HUP0003110A2 (hu) 2001-05-28
WO2001054669A1 (en) 2001-08-02
IL150513A (en) 2012-12-31
ES2171123B1 (es) 2003-11-16
EP2133070A1 (en) 2009-12-16
CN1149997C (zh) 2004-05-19
FI20001749A0 (fi) 2000-08-04
ATE232088T1 (de) 2003-02-15
YU5202A (sh) 2004-12-31
PL341853A1 (en) 2001-01-29
SE0002826D0 (sv) 2000-08-04
AT412062B (de) 2004-09-27
EP2774609A1 (en) 2014-09-10
CA2315141A1 (en) 2001-07-26
TR200201888T2 (tr) 2002-11-21
IL147870A0 (en) 2002-08-14
AP1449A (en) 2005-07-28
AT412063B (de) 2004-09-27
EP1223918B1 (en) 2003-02-05
AU2005202392B2 (en) 2008-11-20
EE04990B1 (et) 2008-04-15
GB2358582A (en) 2001-08-01
EE05221B1 (et) 2009-10-15
TR200200270T2 (tr) 2002-06-21
AP2002002591A0 (en) 2002-09-30
GB2358583B (en) 2002-02-06
GB0001621D0 (en) 2000-03-15
BR0003364A (pt) 2001-09-18
ZA200003998B (en) 2000-08-14
HK1036935A1 (en) 2002-01-25
AU5184100A (en) 2001-08-02
JP3267960B2 (ja) 2002-03-25
AR023624A1 (es) 2002-09-04
CA2639407A1 (en) 2001-07-26
NO327554B1 (no) 2009-08-10
DK178242B1 (da) 2015-09-28
CZ20002883A3 (cs) 2000-10-11
NL1015859C2 (nl) 2001-10-16
HRP20080525A2 (en) 2008-12-31
FI20001750L (fi) 2001-07-27
CZ20002884A3 (cs) 2001-09-12
AU2000264559A1 (en) 2001-08-07
BE1013413A3 (fr) 2001-12-04
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
EP1251831A1 (en) 2002-10-30
HRP20020097B1 (hr) 2010-12-31
JP2001206877A (ja) 2001-07-31
KR20030036492A (ko) 2003-05-09
DE60001371T2 (de) 2004-01-22
BG66159B1 (bg) 2011-09-30
CA2313783A1 (en) 2000-10-16
BG106393A (en) 2002-07-31
PL196808B1 (pl) 2008-02-29
YU52902A (sh) 2006-01-16
JP2007182452A (ja) 2007-07-19
US6548513B1 (en) 2003-04-15
MY122707A (en) 2006-04-29
HUP0003110A3 (en) 2003-02-28
GB2358582B (en) 2004-09-29
AP1879A (en) 2008-08-14
BG106926A (bg) 2003-04-30
KR100698333B1 (ko) 2007-03-23
JP2001206847A (ja) 2001-07-31
SE523481C2 (sv) 2004-04-20
IS6480A (is) 2002-07-23
PT102503B (pt) 2004-02-27
NL1015858C2 (nl) 2001-07-27
CR10114A (es) 2008-08-21
SI1223918T1 (en) 2003-06-30
HK1040936A1 (zh) 2002-06-28
IL147870A (en) 2003-10-31
NO20003967L (no) 2001-07-27
CN1319396A (zh) 2001-10-31
HK1048950A1 (zh) 2003-04-25
ZA200003997B (en) 2000-08-14
DE10038110B4 (de) 2006-06-29
AU781269B2 (en) 2005-05-12
ATA13612000A (de) 2004-02-15
CR6568A (es) 2004-03-05
CA2313783C (en) 2002-03-12
AP2002002409A0 (en) 2002-03-31
IS6254A (is) 2002-01-29
ITTO20000779A1 (it) 2002-02-04
CA2639407C (en) 2011-09-13
CN1282581A (zh) 2001-02-07
HU222578B1 (hu) 2003-08-28
PT102504A (pt) 2001-07-31
UA77156C2 (en) 2006-11-15
GB0019029D0 (en) 2000-09-27
CZ290167B6 (cs) 2002-06-12
IL187416A0 (en) 2008-02-09
CN100528161C (zh) 2009-08-19
DE60001371D1 (de) 2003-03-13
EP1223918A1 (en) 2002-07-24
TR200701171T2 (tr) 2007-04-24
AU2005202392A1 (en) 2005-06-30
KR100388713B1 (ko) 2003-06-25
EE200900047A (et) 2011-04-15
EE05586B1 (et) 2012-10-15
SE0002826L (sv) 2001-07-27
HU0003111D0 (en) 2000-10-28
NO20003968L (no) 2001-07-27
FI20105657L (fi) 2010-06-10
DE10038110A1 (de) 2001-08-23
FI111806B (fi) 2003-09-30
PT1223918E (pt) 2003-06-30
PL341855A1 (en) 2001-07-30
TW553749B (en) 2003-09-21
KR20000072135A (ko) 2000-12-05
NO20003967D0 (no) 2000-08-04
PT102503A (pt) 2000-12-29
FR2804025A1 (fr) 2001-07-27
BE1013414A5 (fr) 2001-12-04
GB0019028D0 (en) 2000-09-27
ITTO20000780A1 (it) 2000-11-04
CL2007001807A1 (es) 2008-01-18
JP4800988B2 (ja) 2011-10-26
HK1040936B (zh) 2010-06-11
ES2171123A1 (es) 2002-08-16
NO20003968D0 (no) 2000-08-04
NZ531474A (en) 2007-04-27
BG66168B1 (bg) 2011-10-31
FR2795324B1 (fr) 2002-05-17
FI20001750A0 (fi) 2000-08-04
KR20010077840A (ko) 2001-08-20
DK200001171A (da) 2001-07-27
EE200200411A (et) 2003-12-15
IS2805B (is) 2012-09-15
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
AU6580000A (en) 2001-08-07
BG110353A (en) 2009-09-30
HRP20020632B1 (en) 2010-12-31
SE0002827D0 (sv) 2000-08-04
SE523471C2 (sv) 2004-04-20
CH691347A5 (de) 2001-07-13
EE200200052A (et) 2003-04-15
DK200001170A (da) 2001-01-27
ATA13602000A (de) 2004-02-15
HUP0003111A2 (hu) 2002-02-28
AU5184200A (en) 2001-08-02
AU2005202392C1 (en) 2016-06-02
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
NO2010005I1 (no) 2010-05-03
NO327675B1 (no) 2009-09-07
DK1223918T3 (da) 2003-04-28
HK1200368A1 (en) 2015-08-07
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
SK11792000A3 (sk) 2001-12-03
TWI228050B (en) 2005-02-21
EP2018853A1 (en) 2009-01-28
FR2804025B1 (fr) 2002-08-23
ITTO20000779A0 (it) 2000-08-04
EP2266540A1 (en) 2010-12-29
NZ519774A (en) 2004-04-30
CH700184B1 (de) 2010-07-15
IL150513A0 (en) 2003-02-12
CR6687A (es) 2005-07-18
AU781269C (en) 2006-11-30
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
SK283872B6 (sk) 2004-03-02
ES2155043B1 (es) 2001-12-01
SK11782000A3 (sk) 2001-12-03
NO312434B1 (no) 2002-05-13
NO20071303L (no) 2001-07-27
HRP20020632A2 (en) 2004-12-31
AU738074B2 (en) 2001-09-06
AR025055A1 (es) 2002-11-06
HU0003110D0 (en) 2000-10-28
CZ299105B6 (cs) 2008-04-23
SE0002827L (sv) 2001-07-27
BG65234B1 (bg) 2007-09-28
HUP0003111A3 (en) 2003-03-28
DE10038108A1 (de) 2001-08-02
MY123650A (en) 2006-05-31
BR0003365A (pt) 2001-09-18
RS50201B (sr) 2009-07-15
FI121365B (fi) 2010-10-29
UA51853C2 (uk) 2002-12-16
AR060248A2 (es) 2008-06-04
FR2795324A1 (fr) 2000-12-29
IS8620A (is) 2007-03-07
HK1047052A1 (zh) 2003-02-07
CA2315141C (en) 2009-08-18
NL1015859A1 (nl) 2001-07-27

Similar Documents

Publication Publication Date Title
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE60002193D1 (de) Metalloprotease inhibitoren
DK1524266T3 (da) Farmaceutisk sammensætning
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
IS5248A (is) Lyfjasamsetningar sem innihalda vorikónasól
IL152659A0 (en) Pharmaceutical composition
HUP0300544A3 (en) Pharmaceutical compositions containing integrin expression inhibitors
IS6263A (is) Lyfjasamsetningar, sem innihalda trípeptíð
ITMI20010748A0 (it) Composizioni farmaceutiche
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
MA26818A1 (fr) Formulations contenant des inhibiteurs de lipase
HUP0204555A3 (en) Pharmaceutical composition
HUP0001632A3 (en) Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
NO20026123L (no) Farmasöytiske sammensetninger
NO20031095D0 (no) Farmasöytiske sammensetninger
IS6021A (is) Lyfjasamsetningar sem innihalda sítalópram
GB0030284D0 (en) Enzyme inhibitors
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
IL153487A0 (en) Pharmaceutical compositions and methods for use
IL153897A0 (en) Pharmaceutical compositions and methods for use
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
GB0005382D0 (en) Pharmaceutical composition
EE200200689A (et) Ravimkoostised
GB0002691D0 (en) Pharmaceutical composition